Assessment of the fatty liver index as an indicator of hepatic steatosis for predicting incident diabetes independently of insulin resistance in a korean population

Diabetic Medicine

Volumn 30, Issue 4, 2013, Pages 428-435

  Jung, C H ^a   Lee, W J ^a   Hwang, J Y ^a   Yu, J H ^a   Shin, M S ^a   Lee, M J ^a   Jang, J E ^a   Leem, J ^a   Park, J Y ^a   Kim, Hong Kyu ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASSESSMENT OF HUMANS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL INDICATOR; CONTROLLED STUDY; FATTY LIVER; FATTY LIVER INDEX; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INCIDENTAL FINDING; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KOREAN (PEOPLE); LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RISK; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SOUTH KOREA;

DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; ODDS RATIO; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84879743065     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12104     Document Type: Article

References (30)

1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387–1395.
2. Park SH. Current status of liver disease in Korea: nonalcoholic fatty liver disease. Korean J Hepatol 2009; 15: S34–39.
3. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010; 69: 211–220.
4. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med 2008; 25: 476–481.
5. Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of Type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 2011; 34: 727–729.
6. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of Type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1093–1097.
7. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36: 437–441.
8. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.
9. Balkau B, Lange C, Vol S, Fumeron F, Bonnet F. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol 2010; 10: 56.
10. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. J Am Med Assoc 2009; 301: 2129–2140.
11. American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care 2012; 35: S11–63.
12. Chen H, Sullivan G, Yue LQ, Katz A, Quon MJ. QUICKI is a useful index of insulin sensitivity in subjects with hypertension. Am J Physiol Endocrinol Metab 2003; 284: E804–812.
13. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537–1544.
14. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007; 22: 1086–1091.
15. Hsieh PS, Hsieh YJ. Impact of liver diseases on the development of Type 2 diabetes mellitus. World J Gastroenterol 2011; 17: 5240–5245.
16. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord 2003; 27: S6–11.
17. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-b and NF-jB. Nat Med 2005; 11: 183–190.
18. Ishikawa J, Tamura Y, Hoshide S, Eguchi K, Ishikawa S, Shimada K et al. Low-grade inflammation is a risk factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives: the Jichi Medical School ABPM Study, wave 1. Stroke 2007; 38: 911–917.
19. Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab 2010; 12: 483–495.
20. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763–770.
21. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Haring HU et al. Plasma fetuin-A levels and the risk of Type 2 diabetes. Diabetes 2008; 57: 2762–2767.
22. Oike Y, Akao M, Yasunaga K, Yamauchi T, Morisada T, Ito Y et al. Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nat Med 2005; 11: 400–408.
23. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627–1635.
24. Yang SJ, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG et al. Serum selenoprotein P levels in patients with Type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab 2011; 96: E1325–1329.
25. Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab 2008; 93: 4479–4485.
26. Yilmaz Y, Ulukaya E, Atug O, Dolar E. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. Eur J Gastroenterol Hepatol 2009; 21: 1247–1251.
27. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082–1090.
28. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462–E468.
29. Kim JH, Kwon SY, Lee SW, Lee CH. Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population. Liver Int 2011; 31: 1600–1601.
30. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157–163.